FDA’s new CSA guidance: transforming software validation for production and quality systems

FDA’s final guidance on Computer Software Assurance (CSA) for Production and Quality System Software marks a significant modernization of software validation practices.

Multiplex immunofluorescence chemistries with ZEISS tissue multiplexing workflow

Bringing leading multiplex immunofluorescence chemistries together in one automated 8-channel imaging platform.

ZEISS showcases comprehensive workflow for full spectrum of retina care at EURETINA

ZEISS Medical Technology combines its diagnostic, surgical and digital technologies to support healthcare professionals in advancing retinal care.

The Future of Metrology is Coming to Your Region

Join our event series.

ZEISS unveils AI-powered Research Data Platform

Collaboration with Boehringer Ingelheim champions the future of personalized eye care.

Här är orden som tvättas bort i Trumps USA

Den amerikanska smittskyddsmyndigheten CDC uppmanar sina forskare att dra tillbaka eller pausa alla nya forskningsstudier som är aktuella för publicering i medi...

Discover ZEISS ZEN core – now for electron microscopy

Watch the recording of our free webinar.

Lista: Årets mest framstående medicinska uppfinningar

Den subkutana formen av det svenskutvecklade alzheimerläkemedlet Leqembi lyfts fram när Time presenterar sin årliga lista över de bästa uppfinningarna 2025.

Billion-Dollar Deal Sends BioArctic Soaring

Swedish Alzheimer-focused company BioArctic has entered into a licensing collaboration with Novartis regarding a technology aimed at enhancing efficient drug de...

Anocca raises SEK 440 million ahead of clinical cancer trial

Swedish cell therapy biotech Anocca has successfully raised SEK 440 million in a new funding round to support upcoming clinical trials in pancreatic cancer.

New Insights into Microscopy

Watch the recording of our free webinar.

Allogene discontinues investigational antibody following patient death

U.S. biotechnology company Allogene Therapeutics is fully discontinuing the use of its experimental antibody ALLO-647 following the death of a patient in its pi...

ZEISS receives FDA clearance for INTRABEAM 700

With its new treatment platform for intraoperative radiotherapy, ZEISS is actively shaping the medical innovation of neuro tumor therapy.

Novo Nordisk cuts ties with Hims & Hers after Wegovy dispute

Novo Nordisk is ending its collaboration with Hims & Hers Health due to concerns about the company’s sales and marketing practices related to the weight-loss drug Wegovy.

AstraZeneca to use American AI platform for cancer trials

In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.

FDA godkänner genterapi för sällsynt sjukdom

FDA har godkänt PTC Therapeutics genterapi för att behandla en potentiellt dödlig enzymbrist. Genterapin har varit godkänd i EU sedan 2022 under namnet Upstaza.

ZEISS Lightfield 4D for instant volumetric high-speed imaging

Capturing physiological and neuronal processes in 3D.

Are you curious about volume imaging for very large samples?

Exciting ZEISS Webinar!

New moves around Nykode's management – withdrawal of resignations

Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.

Novartis betalar en miljard dollar för projekt inom sällsynt nervsjukdom

Läkemedelsjätten Novartis betalar en miljard dollar i förskott för de globala rättigheterna till en läkemedelskandidat mot Huntingtons sjukdom, som utvecklas av PTC Therapeutics....

Mavatar AB

Korbinian Löbmann leads scientific meeting on drug formulation: High activity in the field

Korbinian Löbmann has moderated New Updates in Drug Formulation & Bioavailability several times before. Now he is once again taking on the scientific meeting. L...

Affibody AB

Dubbla bakslag för ALS-projekt – ”Inte vad vi hoppats på”

Förhoppningarna om att utveckla en ny typ av behandling mot nervsjukdomen ALS har fått sig en törn när två läkemedelskandidater misslyckats med att nå sina prim...